



Barth Syndrome Foundation, Inc. Board of Directors Meeting April 10, 2014

Members in Attendance:

Marcus E. Sernel Chairman

Lindsay Groff, Executive Director Board Member, ex-officio

David Axelrod, MD Board Member

Randy Buddemeyer Treasurer, Board Member

Stephen Kugelmann Board Member

Susan A. McCormack Secretary, Board Member

Katherine R. McCurdy
Susan Osnos
Board Member
John Wilkins
Board Member
Susan V. Wilkins
Board Member
Kevin Woodward
Board Member

Members Not in Attendance:

Catharine Lynne Ritter Board Member

Lynda Sedefian, Executive Assistant

Additional Invitees

Shelley Bowen, Director, Family Services/Awareness Ellen Bruno, Simple Office Solutions Diane Gibson, Gray, Gray & Gray, LLP

Stephen B. McCurdy Chairman Emeritus

Sandra Stevens, Fundraising Project Manager Matthew J. Toth, PhD, BSF Science Director

Our Mission - Saving lives through education, advances in treatment, and finding a cure for Barth syndrome.

Agenda Items:

- 1. Board Terms & Elections
- 2. Review 2013 Audited Financials
- 3. Review 2014 Year-to-Date Financials
- 4. Review Executive Summary
- 5. Update BRR 2.0
- 6. Update Science & Medicine
- 7. Other

The meeting, held via teleconference, was called to order by the Chairman on Thursday, April 10, 2014 at 8:00 pm ET. Marc officially welcomed Kevin Woodward who was elected to serve on BSF's Board of Directors commencing April 2014 for a three-year term. Said term will run through April 2017.

1. Board Terms

Marc reviewed the term limits of the current Board of Directors. Kate McCurdy and Sue Wilkins's terms ended, as of April 2014, as members of the Board of Directors. Marc thanked Kate and Sue for their dedicated service to BSF.

Randy Buddemeyer, Susan McCormack and John Wilkins's 3-year terms ended as of April 2014. The board voted unanimously to re-elect all three members for an additional 3-year term.

VOTED: That the Board of Directors re-elect Randy Buddemeyer to serve an additional 3-year term. Said term will run through April 2017.

VOTED: That the Board of Directors re-elect Susan McCormack to serve an additional 3-year term. Said term will run through April 2017.

VOTED: That the Board of Directors re-elect John Wilkins to serve an additional 3-year term. Said term will run through April 2017.

2. Review – 2013 Audited Financials

Diane Gibson of Gray, Gray & Gray, LLP was also an invited guest who joined the meeting via teleconference to disclose BSF's 2013 Audited Financial Statements and Form 990. Diane delivered a clean audit of BSF's 2013 financial statements. Diane reviewed the contents of the 2013 audit with the members of the Board who were satisfied with the financial statements and pleased with the findings of BSF's auditor. Following a discussion, it was:

VOTED: That the Board of Directors accept the 2013 Audited Financial Statements and 990, as submitted by Gray, Gray & Gray, Certified Public Accountants, LLC.

At this time, Diane Gibson and Ellen Bruno left the meeting. The Barth Syndrome Foundation will register with all fifteen (15) states where BSF solicits funds concurrently with the filing of its 2013 Auditor's Report and IRS Form 990.

3. Review – 2014 Year-to-Date Financials

Randy Buddemeyer, BSF Treasurer, provided an overview of the 2014 year-to-date budget comparison preliminary financial statements, which reflected the following:

Preliminary Statement of Revenue and Expenditures All Funds – 01/01/2014 – 03/31/2014

Total Revenues of \$60,894; including unrestricted donations of \$57,759.

Total Expenses of \$492,983; and a Total Fund Balance of \$432,089.

Total Current Assets	\$ 1,710,115
Total Current Liabilities	\$ 318,884
Total Fund Balance	\$ 1,391,231

4. Review - Executive Summary

Lindsay introduced Sandra Stevens to the board. Lindsay then provided an executive summary which outlined recent activities among BSF's programs, including: Awareness, Conference, Science & Medicine, Fundraising and Publications/Communications.

Fundraising

Lindsay reported that she and Sandra attended the Principles & Techniques of Fundraising Course at Indiana University on March 24-27, 2014. Both felt it was a very worthwhile training course.

Lindsay reported that the Spring appeal was mailed on April 10, 2014 and will be sent to approximately 700 donors. The theme of the appeal is the 2014 conference. Lindsay and Sandra are planning additional targeted appeals throughout 2014, using techniques learned at the IUPUI training course. They also plan to repeat the Giving Tuesday campaign in November. The Board discussed various issues regarding these fundraising appeals to ensure that are well-received by donors and potential donors.

Lindsay reviewed the overall 2014 priorities which include: drug development possibilities, research grant program, BRR 2.0, 2014 conference, website upkeep, ongoing publications, and enhanced fundraising.

Lindsay reported that conference planning is ongoing. Shelley Bowen has increased emphasis this year on carriers, young men transitioning to adulthood, transplanted individuals, and bereaved families.

5. <u>Update – BRR 2.0</u>

Shelley Bowen reported that the target date for launch is now early May. If there were no further delays the possibility of having a demo of BRR 2.0 at the conference was discussed. Shelley will keep the Board updated on further developments.

6. Update - Science & Medicine

Bezafibrate Initiative

Matt Toth reported on the status of the bezafibrate initiative. Two developments have resulted in a delay in seeking FDA approval of a clinical trial: (1) the FDA raised certain questions and concerns about the proposal that will need to be addressed, and (2) a recent paper was published that might raise questions about the expected efficacy of bezafibrate in treating Barth Syndrome. Matt reports that he and the SMAB still believe that bezafibrate holds great promise as a potential therapy for Barth Syndrome, but that further animal testing should be done to bolster the case for a clinical trial. As a result, Matt requested that the board fund a total of \$100,000 for two labs to perform preclinical bezafibrate studies with the knockdown mouse. It is hoped that with positive data from these studies the FDA will approve a clinical trial of bezafibrate.

VOTED: That the Board of Directors accept Matt's request to fund a total of \$100,000 for two labs to perform pre-clinical bezafibrate studies with the knockdown mouse.

7. Other

The next board meeting will be Monday, June 23, 2014 at 8:00 am ET at the Conference hotel. Board members will be expected to arrive at the conference hotel by Sunday evening.

Marc Sernel will be working with Susan Osnos to further develop a list of potential candidates for Board service.

Adjournment

The meeting was adjourned at 10:20 pm ET. The next Board meeting is scheduled for Monday, June 23, 2014 at 8:00 am ET at the conference location.

Respectfully submitted,

Susal Ma Comple

Susan A. McCormack

Secretary